BIOVF - European advisory group rejects Swedish Orphan's emapalumab for rare inflammatory condition July, 24 2020 11:42 AM Swedish Orphan Biovit Ord The European Medicines Agency's advisory group CHMP has adopted a negative opinion against approval of Swedish Orphan Biovitrum AB's (OTCPK:BIOVF) Gamifant (emapalumab) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in children under the age of 18.More news on: Swedish Orphan Biovitrum AB (publ), Healthcare stocks news, Read more ...